Aurinia Q3 net product revenue $40.8M (+60% YoY); narrows FY2023 guidance to $155-160M

Aurinia Pharmaceuticals Inc.

2023-Q3 EPS reported -$0.36 revenue$130,418,000

Net product revenue $40.8M in Q3, up 60% YoY; 9-month net product revenue $116.2M (+55%).
Narrowed FY2023 net product revenue guidance to $155-160M from prior range.
Net loss $13.4M ($0.09/share) vs $9.0M ($0.06/share) in Q3 2022; 9-month net loss improved to $51.1M from $82.1M.
Patients on LUPKYNIS at Sept 30: ~1,939 (+43% YoY); 436 PSFs added in Q3 (+17%).
Received $10M milestone from Otsuka for European pricing and reimbursement in three major markets.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aurinia Pharmaceuticals Inc. reported three months ended September 30, 2023 results: revenue $54.5 million.

Period: three months ended September 30, 2023
Revenue: $54.5 million
Result: reported results

Exact text from the filing

Total net revenue was $54.5 million for the three months ended September 30, 2023

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aurinia Pharmaceuticals Inc. reported nine months ended September 30, 2023 results: revenue $130.4 million.

Period: nine months ended September 30, 2023
Revenue: $130.4 million
Result: reported results

Exact text from the filing

Total net revenue was $130.4 million for the nine months ended September 30, 2023

View on SEC.gov

35 earnings releases filed in the last 30 days. Browse all earnings releases →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-23-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.